China County Level Hospitals Present New Opportunities
This article was originally published in PharmAsia News
The majority of China’s healthcare resources have long been controlled by top-level hospitals in urban areas. These major facilities, categorized as “san jia yi yuan” (三甲医院), have naturally been the priority target for foreign drug and medical devices manufacturers wanting to score sales in China. But recent moves by China’s National Health and Family Planning Commission (NHFPC) signal that primary hospitals in rural areas should be playing a larger part in companies’ commercial strategies.
You may also be interested in...
An EU guideline on the methodological aspects of pharmacoepidemiology has been updated to promote collaboration by researchers on high-quality, multi-centre observational studies in the context of COVID-19.
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.